Definition
• Anaphylaxis – acute onset skin, mucosal or GI involvement w/ at least 1 of the following: Respiratory distress, hypotension, end-organ Dysfxn
History
• Exposures: Nuts, shellfish, medication (abx, NSAIDs, iodine contrast), insect, ACEI (angioedema), PMH: Hereditary angioedema
• Sx: SOB, swelling of tongue/throat, hoarseness, hives, N/V, abdominal cramps, syncope
Findings
• Urticaria, conjunctival injection, diffuse erythema, swelling (face, tongue, mouth), hoarseness, drooling, stridor, ↓ BP
Evaluation
• Assess airway, potential need for intubation; IV access & fluid resuscitation for anaphylactic shock
• H1 + H2 > H1 antagonist alone for urticaria (NEJM 2004;351:2203)
• IM vs. SC epinephrine: IM preferred → more rapid absorption (J Allergy Clin Immunol 2001;108:871)
• Epinephrine & cardiac dz: Pt should be on monitor; CAD = relat. CI
• Glucocorticoids may prevent recurrence or extended event, though evidence inconclusive
Disposition
• Home w/ 2 epi-pens (one home, one w/ pt)
• Pts w/ either (1) local rxns w/o airway involvement or (2) generalized rxn + presented to ED hours after exposure
• Admit to Obs unit/floor: Any pt requiring epinephrine
• Admit to ICU: Severe anaphylactic rxn, airway compromise
Pearls
• ACEI can cause angioedema at any time, independent of length of use
• PCN allergy: IgE-mediated allergy confers low (∼1%) risk of cross-reactivity w/ cephalosporins; however, avoid if rxn is severe (NEJM 2006;354:601)
ONCOLOGIC EMERGENCIES
NEUTROPENIC FEVER
Approach
• Initiate access, IVFs, abx, & tx of sepsis as early as possible. Pts can deteriorate quickly.
Definition
• Single temp >38.3°C or temp >38°C for 1 h + ANC <500, or <1000 + predicted drop <500, or functionally neutropenic (eg, AML)
• Pts may experience rapid clinical deterioration w/ few presenting signs of inflammation
History
• Date of fever onset, date of cytotoxic therapy (ANC nadir ∼10–14 d after chemo)
Findings
• Examine skin, mouth, lung, abdomen, catheter/surgical sites, perirectal area (DRE)
Evaluation
• CBC w/ differential, Chem 7, LFTs, coags, UA/urine cx, blood cx (at least 2 + any catheter port if present), ±CXR
• ±Additional labs: Coags, culture (stool/sputum/peritoneal/CSF)
• Imaging: Consider imaging of chest, abdomen/pelvis, sinuses, brain
Treatment
• Empiric abx → low risk: Ciprofloxacin + (amoxicillin + clavulanate)
• Empiric abx → high risk: AFTER cx are drawn, cover for resistant Pseudomonas:
• Monotherapy: Ceftazidime, cefepime, or carbapenem (except ertapenem)
• Combination (synergy against GNRs): Aminoglycoside + antipseudomonal PCN or any of the monotherapy drugs
• Vancomycin: For catheter-related infxn, MRSA colonization, ↓ BP
• PCN-allergic → levofloxacin + aztreonam or aminoglycoside
• Antivirals: Acyclovir (if skin lesions c/w herpes/VZV)
Disposition
• Low threshold to admit all pts w/ neutropenic fever
Pearls
• ≥50% pts w/ neutropenic fever have occult infection & ∼60–70% are gram+ (Clin Infect Dis 2002;34:730)
• Atypical organisms, meningitis are rare
TUMOR LYSIS SYNDROME (Oncology 2011;25(4):378)
Approach
• Obtain ECG immediately (look for signs ↑ K), & put on cardiac monitor
Definition
• Rapid destruction neoplastic cells → release of intracellular uric acid, K, PO4
• Defined as ≥2 of abnl serum values (>25% ↑ K, ↑ PO4, ↓ Ca) w/i 3 d before or 7 d after the start of chemotherapy & ≥1 of renal failure (GFR ≤ 60), cardiac arrhythmia, or sz
• Typically 48–72 h after starting cytotoxic cancer tx, a/w large, rapidly proliferating, tx-responsive tumors (esp acute leukemia, NHL, Burkitt)
History
• N/V, lethargy, edema, CHF, hematuria, cardiac dysrhythmia, sz, muscle cramps, tetany, syncope, sudden death
Evaluation
• Chem 7, Ca, PO4, uric acid, BUN/Cr, LDH, UA (urine pH) → ↑ uric acid, ↑ K, ↑ PO4, ↓ Ca; uric acid must be drawn on ice
Treatment
• Treat ↑ K/↑ PO4 & symptomatic ↓ Ca
• IVFs/hydration to maintain UOP > 100 mL/h: Pts typically have ↓ vascular volume
• Isotonic sodium bicarbonate → urine alkalinization → prevents renal precipitation of uric acid
• Allopurinol
• Rasburicase: In consultation w/ oncology → promotes metabolism of uric acid, may reduce need for dialysis, do not give concomitant allopurinol (J Clin Oncol 2001;19:697)
• HD: If persistent ↑ K, severe acidosis, volume overload, uremia, severe ↑ PO4 or ↓ Ca
Disposition
• Admit (floor vs. ICU, depending on severity)
SICKLE CELL DISEASE
(BMJ 2008;337:a1397)
Approach
• Start O2 if pt hypoxemic or having pain
• Pain medication: Start early, check w/ hematologist for dose
• Abx: If infection is suspected, particularly w/ fever (many pts are functionally asplenic)
Definition
• Pathophysiology: Recessive β-globin mutation → structurally abnl HbS → deoxygenate form polymerizes → RBC sickles → hemolysis/microvascular occlusion
• Anemia: Chronic (hemolysis 2/2 sickling), acute (parvovirus B19, splenic sequestration)
• Microvascular occlusion: Pain crisis, acute chest syndrome, stroke, splenic sequestration, renal necrosis, aseptic necrosis, priapism
• Infection: Sepsis from encapsulated organisms (S. pneumoniae, N. meningitidis, H. influenzae) after splenic infarction & osteomyelitis (Salmonella, S. aureus)
History
• CP, SOB, bone pain (back, extremities)
Findings
• Bone tenderness, tachypnea, ±fever, r/o stroke, priapism
Evaluation
• CBC w/ differential (compare to baseline), chemistries, reticulocyte count (if concern for aplastic crisis or severe hemolysis), LFTs, bilirubin
• CP crisis: CXR (consolidation), ABG, ECG
• Consider other x-ray/MRI (osteomyelitis), CTA chest (PE); CTA/MRI (stroke) prn
Treatment
Acute
• ↓ sickling: O2, IVFs, analgesia w/ opiates (contact hematologist for doses)
• Treat infection w/ abx
• Transfusion for aplastic anemia, splenic sequestration, priapism
• Exchange transfusion: For acute stroke, severe acute chest syndrome
Chronic
• Hydroxyurea: ↑ HbF & ↓ pain crises, frequency & duration of hospitalizations, & risk of acute chest syndrome (NEJM 1995;1332:1317), ↓ mortality (NEJM 2003;1289:1645)
Disposition
• Home: If pain is well controlled
• Admit: Concern for sepsis, acute chest, or hemolytic crisis
Pearl
• Acute chest syndrome: Vaso-occlusion of pulmonary vasculature → pulmonary infarct, consolidation, PNA that resembles ARDS
ABNORMAL BLEEDING: PLATELET DISORDERS AND COAGULOPATHY
Approach
• Stabilize pt (ABCs, IV access/monitor) if necessary
• Differentiate cause of bleeding → PLT vs. coagulation abnlty
• Consult hematology for any pt w/ severe bleeding & known or suspected bleeding d/o
Findings
• Purpura
• Nonpalpable: TCP, PLT Dysfxn, DIC, TTP, cholesterol/fat emboli, scurvy, trauma
• Palpable: Vasculitis, HSP, PAN, RMSF, meningococcemia, bacterial endocarditis
Evaluation
• CBC w/ differential, Chem 7, coags; consider LFTs, peripheral blood smear, DIC panel (fibrinogen, D-dimer, LDH, haptoglobin)
THROMBOCYTOPENIA (TCP) AND PLATELET DYSFUNCTION
Approach
• Isolated TCP: ITP, immune, medications, infection
• TCP + abnl CBC/smear: DIC, HUS, TTP, aplastic anemia, malignancy
Definition
• By PLT count
• <150000: TCP
• >100000: No ↑ risk bleeding
• <50000: Risk of minor bleeding, increased bleeding in trauma
• <20000: Risk of spontaneous bleeding
• <10000: Risk of severe bleeding such as GIB, ICH
History
• PMH (EtOHism, HIV, malignancy, pregnant, meds), infection
Findings
• Splenomegaly, LAD, bleeding
Evaluation
• CBC w/ differential; consider the following:
• Hemolysis w/u: Reticulocyte count, LDH, haptoglobin, bilirubin, peripheral blood smear, coags, fibrinogen, D-dimer, direct Coombs
IMMUNE THROMBOCYTOPENIA (Blood 2010;115(2):168)
Approach
• This is a Dx of exclusion → w/u other etiologies beforehand (TTP/HUS, other immune-mediated dz, drugs, HIV, HCV)
• Consider myelodysplasia in pts >60 y/o
Definition
• Immune Ab-mediated destruction of PLTs (PLT count <100 × 109/L) subdivided into primary (no known cause) & secondary (to viruses, drugs, autoimmune dzs, vaccines)
History
• Gradual onset of petechiae, epistaxis, easy bruising, menorrhagia, hematuria, GIB, recent viral illness
Evaluation
• CBC w/ differential, peripheral blood smear, T + S, Ig levels, HIV/HCV, H. pylori, direct antiglobulin
Treatment
• Rarely indicated for PLTs >50 × 109/L unless increased risk for bleeding or surgery
• Consider hematology consult in adults: Often require tx 2/2 very low PLTs
• Steroids: Prednisone 0.5–2 mg/kg/d w/ taper → short-term utility; give methylprednisolone 1 g/d IV if active bleeding
• If active bleeding or unresponsive to steroids, Anti-Rh(D) Ig: 75 mcg/kg/d IV → for Rh(D)+ pts; IVIG: 1 g/kg/d IV × 1–2 d
• PLT transfusion for bleeding or very low PLTs → use w/ IVIG or Anti-Rh(D) Ig
• Children: Manage mild cases expectantly, treat if PLTs <20000 or active bleeding
• Steroids: Prednisone 4 mg/kg/d PO × 4 d
• Anti-Rh(D) Ig: 75 mcg/kg IV × 2 d
• IVIG: 0.8–1 g/kg IV × 1 dose
Disposition
• Home: If no active bleeding, PLTs >20000
• Admit: Any pt w/ PLTs <20000 &/or active bleeding
Pearls
• Though 50–75% pts respond to steroids, <20% have sustained remission after taper
• ∼50% ITP occurs in children
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) (Chest 2012;141(2 suppl):e495S)
Definition
• Either direct (type I) or Ab-mediated (type II) PLT activation → heparin stimulates formation of IgG → binds to PF4 & heparin on PLT surface → PLT-derived microparticles form & promote thrombin release → ↑ thrombosis
Diagnosis
• PLTs: <150000 or ↓ 30–50% from baseline
• Thrombosis in all vascular beds: eg. PE, DVT, limb ischemia, stroke, MI → up to 50% pts
• Increased heparin resistance
• HIT Ab (PF4-heparin ELISA): ↓ PPV (10–93%) & ↑ NPV (>95%), so send only if intermediate/high PreTP ± confirm w/ PLT aggregation test
History
• Low PLTs ± thrombosis, 5–10 d after starting heparin (rarely causes bleeding), more rapid onset less common but a/w more recent heparin exposure (<30 d)
Treatment (NEJM 2006;355:809)
• STOP heparin + any device/flush that contains heparin
• Consult hematology
• If on therapeutic heparin: Switch to alternative (argatroban, bivalirudin, lepirudin)
• Avoid PLT transfusions unless bleeding or high risk of bleeding
• Future use of heparin (NEJM 2001;344:1286): Risk may be low if negative for PF4 Ab >100 d after Dx
Disposition
• Admit
HEMOLYTIC-UREMIC SYNDROME (HUS) AND THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) (J Intensive Care Med 2007;22(2):82; Br J Haematol 2012;158(3):323; NEJM 2006;354:1927)
Definition
• Systemic (TTP) or intrarenal (HUS) vascular occlusive d/o via PLT aggregation → MAHA (TCP/hemolysis), though their underlying cause is different
• A/w ADAMTS-13 deficiency → inability to cleave vWF → microthrombi
Differential
• Sepsis, DIC, HELLP
History
• HUS:
• HUS triad: MAHA, TCP, renal failure
• Children w/ bloody diarrhea → 2/2 enterohemorrhagic E. coli Shiga toxin
• TTP:
• TTP pentad (uncommon): MAHA, TCP, renal failure, AMS, fever
• Adults → often idiopathic or 2/2 drugs (ie, clopidogrel, chemotherapy, quinidine)
Evaluation
• CBC w/ differential, Chem 7, peripheral blood smear, coags, LFTs, LDH, haptoglobin, fibrinogen, D-dimer, UA
• Dx: MAHA + TCP (same for HUS or TTP)
• MAHA: Evidenced by schistocytes, ↑ LDH, ↑ indirect bilirubin, ↑ Cr (HUS > TTP), ↓ haptoglobin
Treatment
• Consult hematology, consider renal consult early
• TTP:
• Plasma exchange: All pts w/ TTP → ↑ survival @ 6 mo (NEJM 1991;325:393)
• FFP: If there is a delay to plasma exchange
• Steroids: Prednisone 1–2 mg/kg/d, methylprednisolone 1 g/d max 3 d (no well-designed studies evaluating efficacy)
• Low-dose aspirin when PLTs recover (anecdotal evidence), folate supplementation
• HUS: Mainly supportive ± dialysis
Disposition
• Admit
Pearls
• Do not give PLTs → ↑ microvascular thrombosis
• Mortality of TTP is up to 90% w/o tx (NEJM 2006;354:1927), while HUS often resolves w/o tx
VON WILLEBRAND’S DISEASE (vWD) (NEJM 2004;351:683; Haemophilia 2008;14(2):171)
Definition
• vWF defect/↓: A substrate for PLT aggregation/carrier of factor VIII
• Autosomal dominant or recessive, or acquired (eg, malignancy, meds)
History
• Can present like TCP &/or coagulopathy → role w/ PLTs & factor VIII
• Mucocutaneous bleeding & bleeding after surgery, menorrhagia, easy bruising, epistaxis, rarely hemarthrosis, hematoma (severe forms)
Evaluation
• CBC w/ differential (↓ PLTs), Chem 7, coags (↑ PTT), ↓ factor VIII, ↓ vWF: Ag, ↓ vWF activity
Treatment
• Desmopressin (DDAVP): Efficacy is variable, causes endothelial release of vWF
• vWF replacement: Via cryoprecipitate (requires up to 8–12 bags), plasma-derived vWF/factor VIII concentrate (Humate-P), or recombinant vWF, w/ antifibrinolytic amino acids (as adjunct)
Disposition
• Depends on pt’s presentation, severity of vWD, & location of bleeding
Pearl
• Most common inherited bleeding d/o
COAGULOPATHY
Approach
• Differentiate inherited vs. acquired, & tx underlying causes